Articles

Based on a phase 2 trial, interim results exploring the response to ixazomib, lenalidomide, and dexamethasone (IRd) induction followed by a single autologous stem-cell transplantation (ASCT), IRd consolidation, and risk-based maintenance found a 93% overall response rate (ORR). Read More ›

TOURMALINE-MM4 is an international, multicenter, double-blind, placebo-controlled, phase 3 study that examined the efficacy and safety profile of oral ixazomib as maintenance therapy in patients with newly diagnosed multiple myeloma (NDMM) who have not undergone stem-cell transplantation after initial treatment and its impact on progression-free survival (PFS) compared with those taking placebo. Read More ›

The randomized FORTE trial showed that patients who were newly diagnosed with transplant-eligible multiple myeloma (MM) experienced significantly improved progression-free survival (PFS) with carfilzomib plus lenalidomide-dexamethasone (KRd) induction-ASCT-KRd consolidation versus either 12 KRd cycles or carfilzomib plus cyclophosphamide-dexamethasone (KCd) induction-ASCT-KCd consolidation. Read More ›

Comparing consolidation treatment with bortezomib + lenalidomide + dexamethasone (VRD) followed by lenalidomide maintenance with lenalidomide maintenance alone, the former approach was superior regarding progression-free survival (PFS) and myeloma response in patients with newly diagnosed multiple myeloma (MM) with an acceptable toxicity profile. Read More ›

A randomized phase 2 study evaluated the safety and antimyeloma activity of 2 different doses of ixazomib (4 mg or 5.5 mg weekly for 3 weeks with a week off) plus dexamethasone (40 mg weekly) in patients with relapsed multiple myeloma (MM) but who were not refractory to bortezomib; results of this study were reported at the meeting. Read More ›

Researchers presented updated safety and efficacy results of a 2-part study (GEN503) that evaluated combination therapy with the anti-CD38 monoclonal antibody daratumumab plus lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (RRMM). Read More ›

Researchers reported results of a global, multicenter, retrospective International Myeloma Working Group study that assessed the current treatment approaches utilized for initial treatment after first relapse and salvage treatment of patients with multiple myeloma (MM), and examined patient outcomes following successive therapies with the goal of examining the natural history of relapsed MM. Read More ›

Researchers presented results of the randomized, placebo-controlled phase 3 Tourmaline-MM1 study that evaluated the benefit of adding the oral proteasome inhibitor ixazomib to the lenalidomide and dexamethasone (Rd) backbone compared with placebo plus Rd in patients with relapsed and/or refractory multiple myeloma (RRMM). Read More ›

Beth Faiman expresses her excitement about the newly approved multiple myeloma treatments but believes that they will also bring about new challenges. Read More ›

Researchers presented results of the randomized, prospective IFM 2013-04 trial that compared the induction treatment regimens of bortezomib/thalidomide/dexamethasone and bortezomib/cyclophosphamide/dexamethasone prior to autologous stem-cell transplant (ASCT) in patients with de novo multiple myeloma (MM). Read More ›